-
The manufacturer of the abortion pill mifepristone (Mifeprex, Danco Laboratories; New York City) has revised the safety information for the drugs label and issued a letter to health care providers in light of five deaths from serious bacterial infection and sepsis following use of the medication abortion regimen.
-
No doubt you have scanned news reports of a recent study of male circumcision, used as an HIV prevention intervention, which resulted in dramatic reduction in HIV incidence among circumcised men.1 But does the news translate into an immediate change in public health policy?
-
Take a look at www.trichomoniasis.net, the first comprehensive web site to focus on the sexually transmitted disease (STD) trichomoniasis.
-
How do you initiate mini-pills in a lactating woman who specifies such pill use for contraception?
-
If emergency contraception (EC) is made available over the counter (OTC) in the United States, will it lead to more unprotected sex and increased use? Results from a just-published analysis of British use of the drug indicates that it will not.
-
Has your office telephone been ringing with questions from patients following a recent media report that the death rate for the transdermal contraceptive (Ortho Evra, Ortho-McNeil Pharmaceutical, Raritan, NJ) is three times that expected for oral contraceptives?
-
An outbreak of a type of Chlamydia trachomatis, lymphogranuloma venereum (LGV) has occurred in the Netherlands and other European countries, which has led infectious disease officials with the Centers for Disease Control and Prevention (CDC) to ask U.S. clinicians to look out for LGV cases.
-
Make plans now to attend the annual meeting of the Washington, DC-based American College of Nurse-Midwives. Scheduled for June 10-16 in Washington, DC, the event, With Women Through Time, will commemorate the organizations 50th anniversary.
-
What are some of your questions when it comes to hormonal contraceptive use? Two readers questions are tackled below by Leon Speroff, MD, associate director of the Womens Health Research Unit at Oregon Health & Science University in Portland, and David Archer, MD, professor of obstetrics and gynecology and director of the Clinical Research Center at the Eastern Virginia Medical Center in Norfolk.
-
How many women do you see in your practice who say they have chronic or recurrent headaches? If the numbers are high, dont be surprised: Headaches are a frequent occurrence in women of reproductive age. But what is your approach in determining whether these women may use combined oral contraceptives (OCs)?